- Trials with a EudraCT protocol (1,169)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,169 result(s) found for: Levels of biomarkers.
Displaying page 11 of 59.
EudraCT Number: 2021-006224-40 | Sponsor Protocol Number: AxGD | Start Date*: Information not available in EudraCT |
Sponsor Name:Instytut ,,Pomnik-Centrum Zdrowia Dziecka" | ||
Full Title: Evaluation of the safety and efficacy of ambroxol (ABX) use in Polish patients with Gaucher disease, presenting neuronopathic type (GD type III, GD3) resulting from homozygous c.1448T>C mutation (p... | ||
Medical condition: Gaucher disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000241-21 | Sponsor Protocol Number: BEL114870 | Start Date*: 2011-06-23 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A clinical and mechanistic proof of efficacy study with belimumab in chronic immune thrombocytopenia (ITP) patients | |||||||||||||
Medical condition: Chronic Immune Thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000243-87 | Sponsor Protocol Number: PC_ASP_003 | Start Date*: 2018-11-19 | |||||||||||
Sponsor Name:Pulmocide Ltd | |||||||||||||
Full Title: An open-label study to assess the safety, pharmacokinetics and pharmacodynamics of inhaled PC945 in adult Cystic Fibrosis (CF) patients with persistent pulmonary Aspergillus fumigatus infection. | |||||||||||||
Medical condition: Pulmonary aspergillosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003011-97 | Sponsor Protocol Number: 69HCL20_0071 | Start Date*: 2020-12-14 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Fluconazole as a new therapeutic tool in hypercalciuric patients with increased 1,25(OH)2D levels. | |||||||||||||
Medical condition: Hypercalciuria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004263-38 | Sponsor Protocol Number: VBP-003 | Start Date*: 2017-02-13 | |||||||||||
Sponsor Name:ReveraGen BioPharma Inc. | |||||||||||||
Full Title: A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD) | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003703-22 | Sponsor Protocol Number: P2-IMU-838-UC | Start Date*: 2018-05-03 | |||||||||||
Sponsor Name:Immunic AG | |||||||||||||
Full Title: A phase 2, multicenter, randomized, double-blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of IMU 838 for induction and maintenance therapy in moderate-to-severe u... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) PL (Completed) PT (Completed) HR (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004097-32 | Sponsor Protocol Number: CA033 | Start Date*: 2009-07-30 | ||||||||||||||||
Sponsor Name:Abraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation | ||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma | ||||||||||||||||||
Medical condition: Metastatic Malignant Melanoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) FR (Completed) ES (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000615-33 | Sponsor Protocol Number: CONSUL2016 | Start Date*: 2016-07-29 | |||||||||||||||||||||
Sponsor Name:Charite Universitaetsmedizin | |||||||||||||||||||||||
Full Title: Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing... | |||||||||||||||||||||||
Medical condition: ankylosing spondylitis (AS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004497-21 | Sponsor Protocol Number: GASPAR | Start Date*: 2021-01-20 | |||||||||||
Sponsor Name:Centre François Baclesse | |||||||||||||
Full Title: Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A phase II study (GASPAR) | |||||||||||||
Medical condition: Resectable gastric or gastroesophageal junction adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005874-11 | Sponsor Protocol Number: 0822-035 | Start Date*: 2009-02-24 | ||||||||||||||||
Sponsor Name:Laboratoires Merck Sharp & Dhome-Chibret | ||||||||||||||||||
Full Title: A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of ... | ||||||||||||||||||
Medical condition: This is an exploratory sub-study of Protocol 018 (Eudract N°2007-002693-66) to identify biomarkers of physical function. This biomarker sub-study will use an ongoing clinical study (Protocol 018) ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002257-37 | Sponsor Protocol Number: UC-0105/1611 | Start Date*: 2017-02-10 |
Sponsor Name:UNICANCER | ||
Full Title: Secured access to nivolumab for adult patients with selected rare cancer types | ||
Medical condition: Unresectable locally advanced or metastatic, non-clear cell renal cell carcinoma, rare head and neck cancer, rare skin cancer, MSI-nonCRC or penile cancer, which is resistant or refractory to stand... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004061-13 | Sponsor Protocol Number: ESR21-21165 | Start Date*: 2022-06-09 | ||||||||||||||||
Sponsor Name:VHIO Vall d’Hebron Institute of Oncology | ||||||||||||||||||
Full Title: Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors | ||||||||||||||||||
Medical condition: MSS and MSI colorectal and endometrial tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004344-19 | Sponsor Protocol Number: LA48-0215 | Start Date*: 2016-03-31 | |||||||||||
Sponsor Name:ApoPharma | |||||||||||||
Full Title: A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease | |||||||||||||
Medical condition: Parkinson’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000447-27 | Sponsor Protocol Number: USKH_VL1 | Start Date*: 2012-07-25 |
Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel | ||
Full Title: Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery | ||
Medical condition: Pharmacokinetic trial in patients, with a good general condition before standard abdominal surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005347-14 | Sponsor Protocol Number: H2020/PHRC-N/2014/GB-01 | Start Date*: 2016-08-25 | |||||||||||
Sponsor Name:CHU DE NIMES | |||||||||||||
Full Title: Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, pla... | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004311-23 | Sponsor Protocol Number: HOTstudy_Thomas11 | Start Date*: 2011-11-29 | ||||||||||||||||
Sponsor Name:University of Edinburgh [...] | ||||||||||||||||||
Full Title: A randomised, placebo controlled trial to study the effect of heme-arginate on heme-oxygenase-1 induction and renal function in recipients of deceased donor renal transplants. | ||||||||||||||||||
Medical condition: Ischaemia-reperfusion injury in renal transplantation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2017-002517-64 | Sponsor Protocol Number: BTG-002814-02 | Start Date*: 2017-12-15 | |||||||||||
Sponsor Name:Biocompatibles UK Ltd | |||||||||||||
Full Title: An open label, single-arm, Phase I/II study of vandetanib-eluting radiopaque embolic beads (BTG-002814) in patients with hepatocellular carcinoma (HCC) without curative options | |||||||||||||
Medical condition: Hepatocellular Carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005043-13 | Sponsor Protocol Number: RG_14-187 | Start Date*: 2016-08-11 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Evaluating different rate control therapies in permanent atrial fibrillation: A prospective, randomised, open-label, blinded endpoint study comparing digoxin and beta-blockers as initial rate contr... | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004876-31 | Sponsor Protocol Number: 204745 | Start Date*: 2016-03-28 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: An open-label, single arm study to investigate the safety, pharmacokinetics and pharmacodynamics of repeat doses of inhaled nemiralisib in patients with APDS/PASLI | |||||||||||||
Medical condition: patients with APDS/PASLI | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003370-27 | Sponsor Protocol Number: DMFMRI201303 | Start Date*: 2014-09-25 |
Sponsor Name:Rainer Rupprecht, Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Regensburg am Bezirksklinikum | ||
Full Title: Functional MRI (fMRI) after challenge and treatment with antidepressants and their relation to the clinical course, to the Hypothalamus-Hypophysis-Adrenocortical Axis and the colon microbiome | ||
Medical condition: Major Depressive Disorder is a chronic stress related disorder characterized by depressed mood and by vegetative and cognitive symptoms. Moreover, genetic, neuroendocrine and neurochemical biomarke... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
